The impact of using film array pneumonia panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK critical care: a multicentre randomised controlled trial and a COVID-19 related observational sub-study

niversity College London0 个研究点目标入组 558 人开始时间: 2019年8月5日最近更新: 2023年9月18日

适应症

试验速览

2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/34099497/ (added 06/09/2023) 2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34620213/ (added 06/09/2023)

•1. About to receive an antimicrobial to treat a suspected lower respiratory infection (LRTI – including suspected HAP/VAP) for the first time, or a change in existing antimicrobial for LRTI because of deteriorating clinical condition. This relates both to spontaneously breathing patients and those who are intubated for any reason
•2. In-patients in a participating ICU/CCU
•3. Hospitalised for > 48 hours
•4. Sufficient volume of airway specimen obtained for routine testing at site plus 200 microlitres for the FilmArray test

•1. Previous inclusion in work programme 3
•2. Concurrent participation in the active phase (defined as within 30 days of primary end point) of an interventional trial not agreed as acceptable for co-enrolment by the local PIs of both trials. Participants will be permitted to co-enrol in studies that do not involve an intervention (e.g. observational studies).
•3. Moribund and/or not expected to live more than 48 h
•4. Presence of an existing directive to withhold life-sustaining treatment
•5. Prisoners or young offenders currently in custody of HM Prison Service or supervised by the probation service

发起方